Home Health Care ContraFect’s CF-301 to enter phase one clinical trials

ContraFect’s CF-301 to enter phase one clinical trials

The Yonkers biotechnology company announces it will begin clinical trials of a treatment for drug-resistant Staph infections.

This content is for Westfair Online members only. Please to view this content. Become a member by Registering Here.

Comments are closed.